Search clinical trials for: Immunoproliferative Disorders

Total 144124 results

Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

B-cell Non-Hodgkin's Lymphoma

China
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Large B-cell Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
Sanofi US Services, Inc

Recruiting

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
University of Sao Paulo
Hospital das Clínicas de Ribeirão Preto; Blood Center of Ribeirao Preto

Not yet recruiting

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma (CARTHEDRALL)

Lymphoma, Non-Hodgkin | Leukemia, Acute Lymphoblastic

Brazil
Hee Young Ju

Not yet recruiting

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Lymphoblastic Leukemia in Children
FengYan Jin

Not yet recruiting

Dynamic Frailty Assessment for Guiding the Treatment in Older Adults With Newly Diagnosed Multiple Myeloma (DFA)

Multiple Myeloma | Frailty
Carl Ola Landgren, MD, PhD
Janssen Scientific Affairs, LLC

Recruiting

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) (REVIVE)

Multiple Myeloma

United States
St. Jude Children's Research Hospital

Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Nodular Lymphocyte-Predominant Hodgkin Lymphoma

United States
Fundacion Clinic per a la Recerca Biomédica

Not yet recruiting

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma (CARTD-BG-1)

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

Spain
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma (OLYMPIA-2)

Follicular Lymphoma (FL)

Spain, United States, Turkey, Thailand, Belgium, Poland, Chile, Italy
University of Erlangen-Nürnberg Medical School

Recruiting

Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD (MinimALL)

Hodgkin Disease | Acute Lymphoblastic Leukemia | Allogeneic Stem Cell Transplantation

Germany
Assiut University

Recruiting

Multiple Myeloma Prognostic Indices

Hematologic Diseases | Multiple Myeloma

Egypt
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL

Lymphoma, Large B-Cell, Diffuse | High-grade B-cell Lymphoma | Follicular Lymphoma Grade 3B | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Hodgkin Lymphoma | Relapse | Refractory

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed/Refractory Non-Hodgkin Lymphoma

United States, Spain, France, Netherlands, Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (SAKK 38/23)

Non-hodgkin Lymphoma, B Cell

Switzerland
Centre Henri Becquerel

Not yet recruiting

Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas (PTCL-SEQ)

Peripheral T Cell Lymphoma

France
Regeneron Pharmaceuticals

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3)

Diffuse Large B-cell Lymphoma (DLBCL)

United States, Spain, Korea, Republic of, Belgium, Austria, Thailand, Singapore, Italy, France, Australia, Turkey, Poland, Czechia, Chile, United Kingdom, Germany
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)

Follicular Lymphoma (FL)

Taiwan, Spain, Israel, United States, Switzerland, Poland, Austria, Turkey, United Kingdom, Czechia, Australia, Italy, Chile
Starton Therapeutics, Inc

Recruiting

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Multiple Myeloma

United States
Innate Pharma

Recruiting

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States, Australia
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Acute Lymphoblastic Leukemia
Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Relapse/Refractory Multiple Myeloma

China
Peking Union Medical College Hospital

Recruiting

Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study

Peripheral T Cell Lymphoma

China
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals

Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Multiple Myeloma | Monoclonal Gammopathy of Renal Significance

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression

Chronic Lymphocytic Leukemia
Hoffmann-La Roche

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE)

Lymphoma

Korea, Republic of, United States, France, Brazil, China, Spain, Australia, Sweden, Taiwan, Italy, United Kingdom
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma

Relapsed/Refractory Marginal Zone Lymphoma

China
Zhujiang Hospital

Recruiting

A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.

Multiple Myeloma | M Protein

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Australia
Beijing Tongren Hospital

Recruiting

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

B-cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Xijing Hospital

Recruiting

Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia

China
Bambino Gesù Hospital and Research Institute

Not yet recruiting

Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL

B-cell Acute Lymphoblastic Leukemia
Kite, A Gilead Company

Recruiting

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

Relapsed/Refractory Large B-cell Lymphoma

United States, Australia, Canada
The First Affiliated Hospital of Soochow University

Recruiting

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

B Acute Lymphoblastic Leukemia | High Risk Acute Lymphoblastic Leukemia | Ph-Negative ALL

China
BeiGene

Recruiting

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

CLL

Australia, United States, New Zealand, Korea, Republic of, Canada, Puerto Rico
Hunan Province Tumor Hospital

Recruiting

Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

Advanced Solid Tumors or Lymphomas

China
Massachusetts General Hospital

Recruiting

Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma (THRIVE-M)

Multiple Myeloma

United States
Acrotech Biopharma Inc.

Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO)

Peripheral T Cell Lymphoma

United States
University College, London
Hoffmann-La Roche

Not yet recruiting

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (PORTAL)

Large B-cell Lymphoma
Sichuan University

Not yet recruiting

Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

Leukemia, Lymphoid

China
Sichuan University

Not yet recruiting

Immune Reconstitution After Allo-HSCT and Blinatumomab

Leukemia, Lymphoid
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

Acute Lymphoblastic Leukemia, Pediatric

United States
Power Life Sciences Inc.

Not yet recruiting

Navigating the Clinical Research Process for Lymphoma

Lymphoma

United States
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance (FIL_FollVax22)

Follicular Lymphoma

Italy
Ruijin Hospital

Not yet recruiting

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma (ENKTL)

NK-T-Cell Lymphoma, Extranodal

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

the Safety and Efficacy of SENL103 Autologous T Cell Injection

Multiple Myeloma

China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma

Multiple Myeloma in Relapse

China
Epizyme, Inc.
Ipsen

Not yet recruiting

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation (Mandolin)

Follicular Lymphoma | Refractory Follicular Lymphoma

3

Subscribe